Ticker
JNJ

Price
163.42
Stock movement up
+1.42 (0.88%)
Company name
Johnson & Johnson
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
427.26B
Ent value
516.43B
Price/Sales
4.45
Price/Book
5.73
Div yield
2.77%
Div growth
6.03%
Growth years
58
FCF payout
119.38%
Trailing P/E
22.30
Forward P/E
15.76
PEG
3.48
EPS growth
-0.30%
1 year return
-4.87%
3 year return
2.82%
5 year return
2.61%
10 year return
8.30%
Last updated: 2023-01-31

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...
Operations comments

In 21Q1 JNJ COVID-19 Vaccine authorized by U.S. FDA for emergency use

In 21Q1 JNJ Single-Shot COVID-19 Vaccine granted emergency use listing by the World Health Organization

In 21Q1 JNJ Single-Shot COVID-19 Vaccine granted conditional marketing authorization by European Commission

The company has not provided an official guidance for COVID-19 Vaccine revenues and margins for 2021

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share4.52
Dividend yield2.77%
Payout frequencyQuarterly
Maximum yield3.64%
Average yield2.68%
Minimum yield2.36%
Discount to avg yield3.00%
Upside potential3.09%
Yield as % of max yield76.09%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield2.77%
Current yield distribution27.54%
Yield at 100% (Min)2.36%
Yield at 90%2.49%
Yield at 80%2.55%
Yield at 50% (Median)2.68%
Yield at 20%2.81%
Yield at 10%2.90%
Yield at 0% (Max)3.64%

Dividend per share

Loading...
Dividend per share data
Years of growth58 years
CCC statusDividend Champion
Dividend per share4.52
Payout frequencyQuarterly
Ex-div date17 Feb 2023
EPS (TTM)7.20
EPS (1y forward)10.37
EPS growth (5y)-0.30%
EPS growth (5y forward)6.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
JNJS&P500
DGR MR6.60%11.59%
DGR TTM6.60%10.54%
DGR 3 years5.87%4.00%
DGR 5 years6.03%5.65%
DGR 10 years6.37%7.37%
DGR 15 years6.97%5.83%
Time since last change announced289 days
EPS growth (5y)-0.30%
EPS growth (5y forward)6.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM60.13%119.38%
Average--
Forward43.59%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E22.30
Price to OCF19.80
Price to FCF44.28
Price to EBITDA29.02
EV to EBITDA35.08

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.45
Price to Book5.73
EV to Sales5.38

FINANCIALS

Per share

Loading...
Per share data
Current share count2.61B
EPS (TTM)7.20
FCF per share (TTM)3.63

Income statement

Loading...
Income statement data
Revenue (TTM)96.04B
Gross profit (TTM)64.76B
Operating income (TTM)23.40B
Net income (TTM)19.16B
EPS (TTM)7.20
EPS (1y forward)10.37

Margins

Loading...
Margins data
Gross margin (TTM)67.43%
Operating margin (TTM)24.36%
Profit margin (TTM)19.95%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash11.36B
Net receivables15.89B
Total current assets65.24B
Goodwill33.38B
Intangible assets40.34B
Property, plant and equipment46.68B
Total assets175.12B
Accounts payable10.15B
Short/Current long term debt32.03B
Total current liabilities45.54B
Total liabilities100.53B
Shareholder's equity74.60B
Net tangible assets-217.00M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)21.58B
Capital expenditures (TTM)3.84B
Free cash flow (TTM)9.65B
Dividends paid (TTM)11.52B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity25.68%
Return on Assets10.94%
Return on Invested Capital17.97%
Cash Return on Invested Capital9.05%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open161.70
Daily high163.43
Daily low161.07
Daily Volume9.00M
All-time high186.01
1y analyst estimate185.05
Beta0.57
EPS (TTM)7.20
Dividend per share4.52
Ex-div date17 Feb 2023
Next earnings date18 Apr 2023

Downside potential

Loading...
Downside potential data
JNJS&P500
Current price drop from All-time high-12.14%-14.91%
Highest price drop-38.78%-56.47%
Date of highest drop11 Aug 19939 Mar 2009
Avg drop from high-9.38%-11.49%
Avg time to new high19 days13 days
Max time to new high1038 days1805 days
COMPANY DETAILS
JNJ (Johnson & Johnson) company logo
Marketcap
427.26B
Marketcap category
Large-cap
Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Employees
141700
SEC filings
CEO
Alex Gorsky
Country
USA
City
New Brunswick
Stock type
Common stock
CCC status
Dividend Champion
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Plus, Corrado Russo, head of global securities at Hazelview Investments, shares some insight for real estate investors.
February 1, 2023
The company’s court loss over baby-powder litigation could force it to defend thousands of lawsuits case by case, just as it navigates the biggest restructuring in its 137-year history.
January 31, 2023
(Bloomberg) -- A courtroom loss by Johnson & Johnson is threatening a legal maneuver developed by a handful of the most profitable companies in the world to fight lawsuits.Most Read from BloombergSony...
January 31, 2023
Bloomberg Sony Scales Back PlayStation VR2 Output After Disappointing Pre-Order Numbers Sony Group Corp (NYSE: SONY) has reportedly slashed its forecast for shipments of the PlayStation VR2 scheduled ...
January 31, 2023
In this article, we discuss 10 best February dividend stocks to buy. You can skip our detailed analysis of dividend investment and returns of dividend stocks over the years, and go directly to read 5 ...
January 31, 2023
Companies in The News Are: F, AMD, DVN, JNJ
January 31, 2023
A federal appeals court in Philadelphia rejected Johnson & Johnson's (NYSE: JNJ) use of chapter 11 bankruptcy to offload several lawsuits over its talc products, alleging its talc products caused canc...
January 31, 2023
The pharmaceutical company is bracing for a top-line dip. Pfizer said it expects Covid-19 vaccine sales to drop to $13.5 billion in 2023.
January 31, 2023
The comedian Groucho Marx said he would never want to join a club that would have him as a member. US companies are fond of ditching tricky liabilities via the so-called “Texas two-step”. J&J create...
January 31, 2023
Ford follows Tesla as it cuts prices for its Mustang EV, J&J’s talc lawsuits bankruptcy bid is rejected, ‘Super Bowl foods’ are less expensive, and other news to start your day.
January 31, 2023
Next page